A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

Completed · Phase 1 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

The purpose of this study is to investigate the pharmacokinetics and safety of OPA-15406 in adult subjects with atopic dermatitis

Key facts

Study ID

NCT01702181

Run by

Otsuka Pharmaceutical Development & Commercialization, Inc.

People needed

92

Starts

2012-08-01

Expected to finish

2013-12-01

Last updated by the study team

2014-01-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult subjects 18-65 years of age
• Diagnosis of atopic dermatitis (AD)
• AD affecting at least 5% of total Body Surface Area (BSA) for Part 1 and at least 10% BSA for Part 2, not including face, neck, and head
• Have had a positive but inadequate response to one or more treatment course of standard AD therapy including topical steroids, UV light A, narrowband UV B, and UV light B.

You may not qualify if…

• Use of systemic or topical therapy for contact or atopic dermatitis within 30 days of screening

Where it is running

• Study site — Mobile, Alabama, United States
• Study site — Hot Springs, Arizona, United States
• Study site — Irvine, California, United States
• Study site — Orange Park, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Carmel, Indiana, United States
• Study site — Berlin, New Jersey, United States
• Study site — High Point, North Carolina, United States
• Study site — Portland, Oregon, United States
• Study site — College Station, Texas, United States
• Study site — Dallas, Texas, United States
• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.